Medeze Unveils Plans for Advanced Medical Product Backed by Government Support

Key Takeaways

MEDEZE Group is collaborating with the Thai government to develop Advanced Therapy Medicinal Products (ATMPs) and stem cell therapies.
The initiative aims to establish five “Sandboxes” for research and development, enhancing the bioeconomy and treatment quality in Thailand.
Dr. Weerapol Khemarangsan highlights confidence in the partnership’s potential to improve health solutions and revenue growth for the company.

Government Initiative Boosts MEDEZE’s Growth Prospects

MEDEZE Group Public Company Limited (SET: MEDEZE) is gearing up to benefit from a new initiative by the Ministry of Public Health, focused on developing Advanced Therapy Medicinal Products (ATMPs) and stem cell therapies. This initiative aims to enhance the quality of medical treatments and stimulate the nation’s bioeconomy. Currently, the company is in preliminary discussions to set up five designated “Sandboxes,” with one planned for Bangkok and one for Phuket, though specific locations are yet to be confirmed by government agencies.

Dr. Weerapol Khemarangsan, the CEO of MEDEZE, revealed that a declaration signed on February 19, 2025, by the Ministry, in conjunction with four top medical faculties, emphasizes the development of ATMPs. These innovative products leverage gene, stem cell, or tissue technologies to potentially address genetic disorders and previously untreatable diseases. The global ATMPs market was valued at $22.8 billion in 2024, with treatment prices ranging from THB 3 to 30 million per session. Thailand is aiming to ensure its citizens have access to standard ATMPs by 2025 and plans to introduce at least two domestic ATMPs by 2026 along with five research and service centers, projected to generate an economic value of THB 1.5 billion annually.

Despite initial unfamiliarity among the public, MEDEZE’s listing on the Stock Exchange of Thailand (SET) has elevated awareness of high-tech medical solutions. As the company approaches the launch of the “Sandboxes,” it recognizes the importance of public-private partnerships to advance research and development in this high-investment field. The CEO stressed the current need for tangible advancements in medical treatment, pointing out that global advancements could significantly enhance treatment quality.

Emphasizing the need for clear standards and protocols, Dr. Weerapol envisions the “Sandbox” as a collaborative knowledge hub that aids in developing medical indications and promotes technological advancements in healthcare. MEDEZE is also pursuing innovative avenues such as researching Cell Nutrition to mitigate health risks tied to hair dye chemicals, which could diminish the frequency of hair dyeing.

Presently, ATMPs are limited to specialized medical facilities due to their high-risk nature. Dr. Weerapol is optimistic that within four to five years, the standards for these advanced products will align with public demand. He forecasts considerable revenues within the next two years stemming from conditions like osteoarthritis and liver diseases.

Targeting a 25-30% revenue increase in 2025 while venturing into ASEAN markets, MEDEZE aims to evolve into one of Asia’s largest biotech firms. The company is dedicated to achieving significant innovations for national health and positioning itself as a pride of the Thai people while ensuring attractive returns for investors, according to Dr. Weerapol.

The content above is a summary. For more details, see the source article.